EMPACOMBO MET XR FILM-COATED TABLETS

Active Ingredients: Empagliflozin + Metformin Hydrochloride
Extended-Release (XR) Film-Coated Tablets

Available strengths:

• Empagliflozin 5 mg + Metformin 1000 mg
• Empagliflozin 10 mg + Metformin 1000 mg
• Empagliflozin 12.5 mg + Metformin 1000 mg
• Empagliflozin 25 mg + Metformin 1000 mg

Medical Description

Empacombo Met XR combines two oral glucose-lowering medicines with complementary mechanisms: empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, and metformin, a biguanide. The combination is used as part of an overall treatment program for adults with type 2 diabetes mellitus, together with appropriate diet and physical activity, when treatment with the individual medicines or combination therapy is clinically appropriate.

The combination can improve glycemic control while the empagliflozin component may provide additional cardiovascular and kidney benefits in appropriate patients. Current American Diabetes Association (ADA) Standards of Care recognize SGLT2 inhibitors such as empagliflozin as important therapies for people with type 2 diabetes who have cardiovascular disease, heart failure, or chronic kidney disease.

How It Works

Empagliflozin:
Empagliflozin inhibits SGLT2 in the kidneys, reducing the reabsorption of filtered glucose and increasing urinary glucose excretion. This lowers blood glucose and can also promote modest reductions in body weight and blood pressure. SGLT2 inhibitors may provide cardiovascular and kidney protection beyond their glucose-lowering effect in appropriately selected patients.

Metformin:
Metformin primarily reduces hepatic glucose production and improves insulin sensitivity, helping the body use glucose more effectively. Metformin generally has a low risk of causing hypoglycemia when used alone. The extended-release formulation may improve gastrointestinal tolerability compared with immediate-release formulations.

Therapeutic Uses

Empacombo Met XR may be prescribed for type 2 diabetes mellitus to improve glycemic control when lifestyle measures alone are insufficient or when combination therapy is appropriate.

The empagliflozin component may be particularly valuable in selected patients with type 2 diabetes who also have:

• Established cardiovascular disease or elevated cardiovascular risk.
• Heart failure.
• Chronic kidney disease.

Current ADA recommendations support the use of an SGLT2 inhibitor with demonstrated cardiovascular and/or kidney benefits in appropriate patients, sometimes irrespective of baseline HbA1c or concurrent metformin use.

Benefits of the Combination

When clinically appropriate, combining empagliflozin with metformin can provide:

• Effective reduction of blood glucose and HbA1c.
• Complementary glucose-lowering mechanisms.
• Low intrinsic risk of hypoglycemia when neither medicine is combined with insulin or insulin-secretagogue therapy.
• Potential modest weight reduction associated with empagliflozin.
• Cardiovascular and kidney benefits associated with empagliflozin in appropriate patients.

Dosage & Administration

The appropriate strength and dosing schedule should be determined by the prescribing physician based on the patient's current diabetes treatment, glycemic control, kidney function, tolerability, and individual treatment goals.

Because this is an extended-release formulation, the tablet should generally be taken with food and swallowed whole. It should not be crushed, split, or chewed unless the specific product's approved prescribing information explicitly permits this.

Kidney function should be assessed before and during treatment because both components require consideration of renal function. Metformin is contraindicated in patients with eGFR below 30 mL/min/1.73 m², while the glucose-lowering effect of SGLT2 inhibitors decreases as kidney function declines.

Important Warnings & Precautions

1. Dehydration and Low Blood Pressure

Empagliflozin increases urinary glucose and fluid excretion and may contribute to volume depletion, dehydration, dizziness, or hypotension, particularly in older adults, patients taking diuretics, or those with reduced kidney function.

Adequate fluid intake should be maintained unless fluid restriction has been specifically recommended by a healthcare professional.

2. Genital and Urinary Infections

Because empagliflozin increases glucose in the urine, it can increase the risk of genital fungal infections and may also be associated with urinary tract infections.

Patients should seek medical advice if they develop persistent genital itching, discharge, burning during urination, fever, pelvic/flank pain, or other symptoms suggestive of infection.

3. Diabetic Ketoacidosis

SGLT2 inhibitors can rarely cause diabetic ketoacidosis (DKA), sometimes even when blood glucose is not extremely elevated.

Patients should seek urgent medical attention for symptoms such as:

• Nausea or vomiting
• Abdominal pain
• Unusual fatigue
• Difficulty breathing
• Confusion
• Excessive thirst or dehydration

The risk may increase during prolonged fasting, severe illness, dehydration, excessive alcohol intake, or periods of markedly reduced carbohydrate intake. ADA guidance specifically recommends educating patients receiving SGLT2 inhibitors about DKA risk and warning signs.

4. Metformin and Lactic Acidosis

Metformin-associated lactic acidosis is rare but potentially serious. The risk increases particularly with severe renal impairment, acute kidney injury, hypoxia, severe illness, or conditions associated with impaired lactate clearance.

Metformin should not be used when eGFR is below 30 mL/min/1.73 m². Kidney function should be monitored regularly during therapy.

5. Vitamin B12

Long-term metformin therapy can be associated with vitamin B12 deficiency. Periodic assessment of vitamin B12 may be appropriate, particularly in patients with anemia, peripheral neuropathy, or other risk factors for deficiency.

Common Possible Side Effects

Potential adverse effects may include:

• Nausea or gastrointestinal discomfort.
• Diarrhea or abdominal discomfort, particularly with metformin.
• Increased urination.
• Genital fungal infections.
• Urinary tract infections.
• Headache.
• Dizziness or symptoms related to dehydration.
• Changes in blood glucose.

The risk of hypoglycemia is generally low when empagliflozin/metformin is used alone, but the risk can increase when it is combined with insulin or insulin-secretagogue medicines such as sulfonylureas.

Contraindications & Situations Requiring Medical Advice

Empacombo Met XR should not be used in patients with contraindications to either component. Particular attention is required in patients with:

• Severe renal impairment or eGFR below the permitted threshold for metformin.
• Metabolic acidosis, including diabetic ketoacidosis.
• Significant dehydration.
• Severe acute illness or conditions associated with reduced tissue oxygenation.
• Known hypersensitivity to empagliflozin, metformin, or any component of the formulation.

Patients should inform their physician before surgery, prolonged fasting, or serious acute illness because temporary interruption of SGLT2 inhibitor therapy may be required in certain circumstances.

Cardiovascular & Kidney Considerations

Empagliflozin belongs to the SGLT2 inhibitor class, which has demonstrated clinically important cardiovascular and kidney benefits in appropriate patient populations. The ADA 2026 Standards recommend SGLT2 inhibitors with demonstrated benefit for people with type 2 diabetes and chronic kidney disease, and recommend appropriate SGLT2 inhibitor therapy in patients with heart failure or cardiovascular disease.

However, these benefits do not mean that every patient taking empagliflozin/metformin will experience cardiovascular or kidney protection. Treatment should be individualized according to the patient's overall medical condition.

Drug & Treatment Considerations

Patients should inform their healthcare professional about all prescription medicines, over-the-counter medicines, supplements, and herbal products they use.

Particular attention may be required when the patient is taking:

• Insulin or sulfonylureas, because of increased hypoglycemia risk.
• Diuretics or other medicines that may contribute to dehydration.
• Medicines affecting kidney function.
• Other glucose-lowering medicines.
• Alcohol, particularly excessive intake.

Blood glucose, HbA1c, kidney function, hydration status, and other relevant clinical parameters should be monitored according to the treating physician's recommendations.

Patient Disclaimer

This information is provided for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Empacombo Met XR is a prescription medicine and should be used only under the supervision of a qualified healthcare professional. The appropriate strength and dose must be individualized according to the patient's blood glucose control, kidney function, other medicines, and medical conditions. Do not start, stop, or change the dose without consulting your physician.

Seek urgent medical attention if severe dehydration, difficulty breathing, persistent vomiting, severe abdominal pain, confusion, or other symptoms suggestive of diabetic ketoacidosis or another serious reaction occur.

References

• American Diabetes Association (ADA), Standards of Care in Diabetes—2026: Pharmacologic Approaches to Glycemic Treatment.
• American Diabetes Association (ADA), Standards of Care in Diabetes—2026: Cardiovascular Disease and Risk Management.
• American Diabetes Association (ADA), Standards of Care in Diabetes—2026: Chronic Kidney Disease and Risk Management.
• National Library of Medicine / PubMed: ADA Standards of Care in Diabetes—2026.

Write a review